Table 1 Baseline characteristics for patients included
Author/year | Study design | Disease | Cohort | Number of patients | Country/region | Age (years old) | FLR volume before (mL) | FLR/TFLV (%) | Quality score (NEWCASTLE - OTTAWA) |
|---|---|---|---|---|---|---|---|---|---|
Chan et al. 2021 [26] | RT | HCC | ALPPS | 46 | China | 58.5 (26–80) | 302.1 (181.9–524.0) | 24.5 (15.7–37.1) | 8 |
HCC | PVE | 102 | 60 (27–85) | 301.1 (142.0–554.0) | 24.9 (11.8–44.5) | ||||
Chebaro et al. 2021 [18] | RT | mainly CRLM | ALPPS | 85 | France | 62 (23–82) | 348 (95–666) | NR | 8 |
mainly CRLM | LVD | 124 | 64 (39–81) | 379 (161–916) | NR | ||||
Heil et al. 2021 [27] | RT | CRLM/HCC/CCC/GBC/others | LVD | 39 | Multi-country | 63 (2–67) | 281 (234–352.1) | 18 (16–23) | 8 |
CRLM/HCC/CCC/GBC/others | PVE | 160 | 67 (58–73) | 294 (233–389.7) | 18.5 (15–25) | ||||
Sparrelid et al. 2021 [28] | RT | CRLM | ALPPS | 71 | Scandinavia | 65 (56.8–69.3) | NR | 21.8 [18.6–25.5] | 7 |
CRLM | PVE | 101 | 66 (59.4–72.5) | NR | 20.9 [17.4–25.3] | ||||
Hasselgren et al. 2021 [21] | RCT | CRLM | ALPPS | 48 | Scandinavia | 64±9 | NR | NR | 9 |
CRLM | TSH | 49 | 63±12 | NR | NR | ||||
Huang et al. 2020 [24] | PT | HCC | ALPPS | 38 | China | NR | NR | NR | 5 |
HCC | PVE | 38 | NR | NR | NR | ||||
Guiu et al. 2020 [29] | RT | LM/CCC/HCC/others | LVD | 29 | France | 62 (26–79) | 484 (233–805) | 22.6 (16.6–37.7) | 8 |
LM/CCC/HCC/others | PVE | 22 | 66 (45–79) | 542 (236–1119) | 27.4 (13.7–47.7) | ||||
Kobayashi et al. 2020 [25] | PT | CRLM/HCC/CCC | LVD | 20 | Switzerland | 65 (25–85) | 547 (435–656) | 35 (28–38) | 8 |
CRLM/HCC/CCC | PVE | 30 | 65 (41–75) | 523 (420–659) | 33 (29–40) | ||||
Baumgart et al. 2019 [30] | RT | CRLM | ALPPS | 8 | Germany | 52 (37–69) | NR | NR | 8 |
CRLM | PVE | 14 | 60.5 (35–74) | NR | NR | ||||
CRLM | PVL | 20 | 62 (36–78) | NR | NR | ||||
CRLM | TSH | 16 | 51.5 (42–70) | NR | NR | ||||
Panaro et al. 2019 [31] | RT | HCC/CRLM/others | LVD | 13 | France | NR | NR | NR | 7 |
HCC/CRLM/others | PVE | 15 | NR | NR | |||||
Robles-Campos et al. 2019 [32] | RT | CRLM | TALPPS | 21 | Spain | 66 (44–83) | NR | 28 (17–37) | 8 |
CRLM | TSH | 21 | 59 (47–74) | NR | 33 (27–43) | ||||
Jiao et al. 2019 [22] | RCT | CRLM/HCC/others | RALPPS | 26 | UK | 62.4±10.2 | NR | 23.1±1.2 | 9 |
CRLM/CCC/others | PVE | 24 | 64.3±8.9 | NR | 23.7±1.1 | ||||
Sandström et al. 2018 [23] | RCT | CRLM | ALPPS | 48 | Norway | 65.4 ± 8.9 | 363 ±85 | NR | 9 |
CRLM | TSH | 49 | 64.9±11.7 | 365 ± 103 | NR | ||||
Chia et al. 2018 [33] | RT | HCC/CRLM/others | ALPPS | 10 | Singapore | 64.7 (51.4–71.1) | 337 (202.8–462.5) | 21.7 (12.3–28.5) | 8 |
HCC/CRLM/others | TSH | 29 | 61 (40.6–68.8) | 319.5 (209–524.5) | 22.2 (15.3–31.9 | ||||
Adam et al. 2016 [34] | RT | CRLM | ALPPS | 17 | France | 58 (23–75) | NR | 24 (11–38) | 7 |
CRLM | TSH | 41 | 58 (32–75) | NR | 30 (19–53) | ||||
Matsuo et al. 2016 [35] | RT | CRLM | ALPPS | 8 | Japan | 68 (62–78) | 303.9±61.1 | NR | 7 |
CRLM/CCC | PVE | 14 | 72 (35–81) | 290.2±72.5 | NR | ||||
Croome et al. 2015 [36] | RT | CRLM/CCC/HCC/others | ALPPS | 15 | USA/Canada | 55.9±12.1 | 312.9±84.7 | 20.1±3.8 | 9 |
CRLM/CCC/HCC/others | PVE | 53 | 59.5±11.3 | 524.9±219.5 | 31.4±13.7 | ||||
Ratti et al. 2015 [37] | RT | CRLM | ALPPS | 12 | Italy | 59 (51–79) | 295±69 | 22±5 | 8 |
CRLM | TSH | 36 | 59 (42–66) | 307±61 | 23±5 | ||||
Tanaka et al. 2015 [38] | RT | CRLM | ALPPS | 11 | Japan | 68 (50–78) | 314.2±74.5 | NR | 7 |
NETLM | TSH | 54 | 63 (35–76) | 291.4±103.2 | NR | ||||
Schadde et al. 2014 [39] | RT | CRLM/HCC/CCC | ALPPS | 48 | Switzerland | 57 (48.5–65) | 367 (286–440) | 23 (18–29) | 8 |
CRLM/HCC/CCC | TSH | 83 | 61 (54–69) | 389 (324–470) | 24 (18–31) | ||||
Shindoh et al. 2013 [40] | RT | CRLM/HCC/NETLM/CCC/GBC/others | ALPPS | 25 | USA | 63 (32–75) | 310 (197–444) | NR | 9 |
CRLM/HCC/NETLM/CCC/GBC/others | PVE | 144 | 58 (33–79) | 275 (135–541) | NR | ||||
van Lienden et al. 2013 [41] | RT | CRLM/HCC/CCC | PVL | 7 | Netherland | 59.4±7.6 | 467 (303–851) | 27.7±7 | 8 |
CRLM/HCC/CCC | PVE | 14 | 60.2±11.6 | 399 (294–517) | 25.8±7.5 | ||||
Knoefel et al. 2013 [42] | RT | CCC/KT/GC/HCC/CRCLM/NETLM | ALPPS | 7 | Germany | NR | 293±58 | NR | 5 |
CCC/KT/GC/HCC/CRCLM/NETLM | PVE | 15 | NR | 295±94 | NR | ||||
Robles et al. 2012 [43] | RT | CRLM | PVL | 20 | Spain | 57 (26–71) | 510 (203–824) | NR | 7 |
CRLM | PVE | 18 | 63 (40–74) | 501 (309–703) | NR | ||||
Aussilhou et al. 2008 [44] | RT | CRLM CRNETLM | PVL | 17 | France | 51±14 | 477±179 | NR | 5 |
CRLM CRNETLM | PVE | 18 | 61±10 | 509±222 | NR | ||||
Capussotti et al. 2008 [45] | RT | CRLM | PVL | 17 | Italy | 63 (52–76) | 204 (110–440) | 17.7 (9.3–29.5) | 6 |
CRLM | PVE | 31 | 64 (37–75) | 204.5 (125–311) | 17.5 (10.7–22.3) | ||||
Broering et al. 2002 [12] | PT | CRLM/HCC/CCC | PVL | 17 | Germany | 63.8±9.2 | 287.8±60.1 | NR | 9 |
CRLM/HCC/CCC | PVE | 17 | 64.4±6.3 | 271.8±95.8 | NR |